Practical Geriatrics ›› 2026, Vol. 40 ›› Issue (10): 1024-1027.doi: 10.3969/j.issn.1003-9198.2026.10.009

Previous Articles     Next Articles

Efficacy and safety of denosumab combined with menatetrenone in the elderly patients with osteoporosis

LIU Shaohao, YOU Xiaohong, ZHAO Xiaojie, ZHOU Cong, YANG Haihua   

  1. Department of Pharmacy, Wuxi Ninth People’s Hospital, Wuxi 214100, China
  • Received:2026-03-17 Published:2026-10-23
  • Contact: YANG Haihua, Email: 13524176683@163.com

Abstract: Objective To evaluate the clinical efficacy and safety of denosumab combined with menatetrenone in the elderly patients with osteoporosis. Methods A total of 183 elderly patients with osteoporosis admitted to Wuxi Ninth People’s Hospital from March 2022 to March 2025 were enrolled. All the patients were divided into a control group (n=92) and a experimental group (n=91) according to different treatment regimens. The control group was given denosumab, and the experimental group was treated with denosumab combined with menatetrenone.The clinical efficacy, bone mineral density (BMD), bone metabolism biochemical markers such as bone alkaline phosphatase (BALP), β-cross-linked C-telopeptide of type Ⅰ collagen (β-CTX), N-terminal propeptide of type Ⅰ procollagen (PⅠNP), serum calcium (Ca), and serum phosphorus (P), Oswestry Disability Index (ODI) score, and incidence of adverse reactions were observed and compared between the two groups after six months. Results After treatment, the total effective rate in the experimental group was significantly higher than that in the control group (95.6% vs 72.8%,P<0.01). The levels of BMD of lumbar spine L2-L4 and hip and bone metabolism biochemical markers were improved in two groups after treatment. The BMD levels of lumbar spine L2-L4 and hip and serum calcium level were significantly higher, while the serum levels of BALP, β-CTX, PⅠNP, P and ODI score were significantly lower in the experimental group than those in the control group (P<0.05). No obvious adverse drug reactions such as myalgia, hypocalcemia, or gastrointestinal reactions occurred in two groups during the treatment period. Conclusions Denosumab combined with menatetrenone can effectively improve bone metabolic status, increase BMD, and shows good safety in the elderly patients with osteoporosis, which has certain clinical promotion value.
   

Key words: osteoporosis, denosumab, menatetrenone, bone mineral density, bone metabolism markers

CLC Number: